(Q51489163)

5 April 2018

title

Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus. (English)

1 reference

5 April 2018

0 references

Rajeev Jain

1

1 reference

5 April 2018

Kwame Osei

2

1 reference

5 April 2018

Stuart Kupfer

3

1 reference

5 April 2018

Alfonso T Perez

4

1 reference

5 April 2018

Jeff Zhang

5

1 reference

5 April 2018

language of work or name

English

0 references

publication date

1 October 2006

1 reference

5 April 2018

published in

Pharmacotherapy

1 reference

5 April 2018

volume

26

1 reference

5 April 2018

page(s)

1388-1395

1 reference

5 April 2018

issue

10

1 reference

5 April 2018

Metabolic and additional vascular effects of thiazolidinediones.

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.10.1388

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.10.1388

Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.10.1388

Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.10.1388

Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.10.1388

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.10.1388

Differentiating members of the thiazolidinedione class: a focus on safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.10.1388

The pathophysiologic basis of efficacy and clinical experience with the new oral antidiabetic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.10.1388

21 January 2018

Oral Antidiabetic Agents

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.10.1388

A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.10.1388

Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.10.1388

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.10.1388

Potential role of oral thiazolidinedione therapy in preserving beta-cell function in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.10.1388

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.10.1388

Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.10.1388

21 January 2018

Identifiers

DOI

10.1592/PHCO.26.10.1388

1 reference

5 April 2018

PubMed ID

16999648

1 reference

5 April 2018